Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$47.84M+4.7%-$50.22M+17.4%-$60.78M+4.2%-$63.42M-9.0%-$58.21M+4.1%
$2.34M+6.7%$2.19M+1.0%$2.17M+14.0%$1.9M+15.5%$1.65M+11.6%
$2.36M+6.4%$2.22M+11.1%$2M+3.7%$1.93M+6.5%$1.81M+3.1%
-$23.98M-8.1%-$22.18M-0.9%-$21.99M+4.5%-$23.02M-1.4%-$22.7M-9.7%
$3.49M+9.6%$3.19M+65.9%$1.92M+101%$957K+19.8%$799K+54.8%
-$3.49M-9.6%-$3.19M-66.2%-$1.92M-101%-$953K-19.9%-$795K-55.3%
$49.24M+138%
-$27.48M-8.3%-$25.37M-6.1%-$23.91M+0.3%-$23.98M-2.0%-$23.5M-10.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Insight Molecular Diagnostics Inc. Common Stock generate?
Insight Molecular Diagnostics Inc. Common Stock (IMDX) generated -$24.0M in operating cash flow over the trailing twelve months.
What is Insight Molecular Diagnostics Inc. Common Stock's free cash flow?
After $3.5M of capital expenditures, Insight Molecular Diagnostics Inc. Common Stock's free cash flow was -$27.5M over the trailing twelve months, down 16.9% year over year.
Where does Insight Molecular Diagnostics Inc. Common Stock's cash flow data come from?
Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.